T2DM is thought to develop as a combination of insulin resistance and pancreatic β-cell failure.1 Therefore, identification of novel treatments that would increase pancreatic insulin secretion while protecting pancreatic β-cells is of great interest. This evidence concerns the gene INS and Insulin resistance.